Topics to be discussed include:
- Lessons to be learned from recent CIA agreements: Separating out individual considerations and identifying across-the-board negotiation points
- How much of your global and domestic business will be covered by the CIA?
- What kind of monitoring controls and systems need to be implemented?
- What kind of restraints on HCP relationships can you enter into?
- What trends about OIG priorities can be extrapolated from recent CIAs?
- Determining the ramifications of multi-violators
- Distinguishing between boiler-plate and investigation specific provisions
- What provisions are subject to modification based on company specific factors?
- Insights into what provisions have been successfully tailored by other companies
- Creating a cooperative relationship with your appointed monitors and communicating effectively with the OIG during the pendency of the CIA
- Proactively fortifying your compliance system based on the requirements of other pharmaceutical and medical device CIAs before negotiating with the government
- Living under a CIA
- Understanding the effects
- Getting the Board of Directors involved
- Discussing the likelihood of “probation” becoming a new standard
- Preparing for potential tax consequences to settlements – distinguishing between repayments and penalties
- Evaluating what constitutes a “reportable event”
- Setting up internal review organizations and data collection as to implementation of programs
- Preparing for allegations of a breach
- Identifying who can enforce CIA conditions
- Comparing jurisdictional views on whether a breach of a CIA can give rise to an action under the False Claims Act
- Updating investigators on what systems have been implemented and providing data on efficacy
- Retaining independent review organizations
For more information, visit the event website.
People
Related Insights
21 October 2024
Events
Legal Overview of the BIOSECURE Act
Foley special counsel John Strom is speaking in the Association for Accessible Medicine’s GRx+Biosims 2024 conference in a panel titled “Legal Overview of the BIOSECURE Act” on October 21.
04 October 2024
Innovative Technology Insights
Decoding California’s Recent Flurry of AI Laws
Governor Newsom signed over 18 AI-related bills into law during September, impacting numerous industries.
17 October 2024
Events
Top Compliance Considerations when Commercializing in the U.S.
Kyle Faget and Nathan "Nate" Beaver, co-chair of Foley's Medical Device and Equipment Area of Focus within the firm's Health Care & Life Sciences Sector, invite you to join us for a webinar on the compliance considerations you need to know when you are commercializing your medical device products in the U.S.